Activity of sorafenib and sunitinib in advanced penile cancer
Thursday, 4 November 2010- A group of researchers from China conducted a study to investigate the use of sorafenib and sunitinib in the treatment of chemotherapy-refractory advanced penile squamous cell carcinoma (SCC).
Yao Zhu and colleagues published their preliminary findings in an online edition of Urologia Internationalis.
Between May 2008 and June 2009, six (6) advanced penile cancer patients were treated with sorafenib or sunitinib in our center. All of them had previously received at least two chemotherapy regimens. Tumour responses were evaluated by radiologic assessment and serum SCC antigen change. Immunohistochemical staining of CD34 and Ki-67 was performed in three paired tumour tissues before and after treatment.
The results showed that in the six patients, one partial response and four stable diseases were observed. Three patients showed pain response and had an improvement in quality of life. After molecular-targeted therapies, reduction in microvessel density and Ki-67 labeling index was observed in paired specimens.
Serum SCC antigen levels were decreased in five patients after one week of medication. The patient who achieved partial response had an SCC antigen reduction of nearly 95% after treatment with sunitinib. Serious adverse events were fatal infection and rupture of the femoral vessel, which were unlikely related to the medication.
"The feasibility and activity of sorafenib and sunitinib in our series suggest that this approach may be a promising alternative in chemotherapy-refractory advanced penile SCC," the researchers concluded.
Source: Yao Zhu,et al., "Feasibility and Activity of Sorafenib and Sunitinib in Advanced Penile Cancer: A Preliminary Report," Urol Int 2010;85:334-340 (DOI: 10.1159/000315432)